ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AUPH Aurinia Pharmaceuticals Inc

5.15
-0.05 (-0.96%)
After Hours
Last Updated: 22:07:21
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aurinia Pharmaceuticals Inc NASDAQ:AUPH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.96% 5.15 5.11 5.18 5.79 5.03 5.68 3,437,711 22:07:21

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences

15/09/2021 6:11pm

Business Wire


Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Aurinia Pharmaceuticals Charts.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:

  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Monday, September 20, 2021 at 2:55 pm ET. (access here)
  • Cantor Global Healthcare Conference on September 30, 2021 at 12:40 pm ET. (access here)

In order to participate in the audio webcasts, interested parties can also register and access presentations under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcasts will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company recently introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

Investor and Corporate Contact: Dana Lynch, Corporate Communications & IR dlynch@auriniapharma.com

1 Year Aurinia Pharmaceuticals Chart

1 Year Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock